Scientists identify key driver in BRAF inhibitor resistant melanoma

Source: News Medical Life Sciences, September 2020

Targeted therapy with BRAF-MEK inhibitors is an effective treatment for patients with advanced melanoma that cannot be surgically removed or has spread to other areas of the body.

However, many patients become resistant to the therapy, and this can often lead to further metastasis. Moffitt Cancer Center researchers who helped develop this type of combination therapy are now working to better understand what leads to this resistance in hopes of developing ways to overcome it.

In a new article published in the Journal of Investigative Dermatology, Moffitt researchers identify erythropoietin-producing hepatocellular receptor A2 (EphA2) as a driver of metastasis and BRAF-MEK inhibitor resistance in melanoma.

READ THE ORIGINAL FULL ARTICLE